In what could represent a significant transformation of the insulin marketplace, Eli Lilly has announced it will slash the price of two of its insulin products by 70%; Humalog and Humulin. And, the company will cap commercially insured and uninsured patients’ out-of-pocket costs at $35 per month.
Eli Lilly To Lower Insulin Prices And Introduce A $35 Out-Of-Pocket Monthly Cap For Commercially Insured And Uninsured Diabetics
